Pharma major Lupin has received the US health regulator's approval to market a generic version of Warner Chilcott Company's 'Ovcon 35' tablets, an oral contraceptive, in the American market, the company said Friday.
The Mumbai-based company has received final approval for its VyfemlaTM Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the US Food and Drugs Administration (USFDA).
"Lupin's US subsidiary Lupin Pharmaceuticals Inc (LPI) shall commence marketing the product shortly," Lupin said in a statement.
The oral contraceptive (OC) market in the US is valued at around $5 billion and is growing at around 8 percent annually.
According to IMS MAT March sales data, Warner Chilcott Company's Ovcon 35 tablets had annual US sales of around $22.3 million.
Lupin entered the OC space in the US market in September 2011 and currently has one of the largest OC pipeline for the US market, with 34 filings and 14 approvals so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app